Gossamer Bio (GOSS)
NASDAQ:GOSS
Want to see GOSS full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.17Same Quarter Last Year
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.Company Guidance
Clinical Efficacy: 6-Minute Walk Distance Improvement
PROSERA Phase III showed a placebo-adjusted improvement of 13.3 meters in 6-minute walk distance (6MWD) at week 24: seralutinib improved 28.2 m from baseline vs 13.5 m for placebo (p = 0.032). The result met the traditional 0.05 significance threshold.
Secondary Endpoints and Risk-Enriched Subgroup
All four key secondary endpoints favored seralutinib over placebo, with a stronger effect observed in the prespecified risk-enriched subgroup, supporting consistency across clinical measures.
Robust Mechanistic Imaging Evidence (CT FRI Substudy)
162 patients enrolled in the prespecified CT FRI substudy with 125 evaluable paired baseline and week-24 scans. Results showed multi-compartment structural reverse remodeling (arterial, venous, fibrosis-like parenchymal and vascular complexity parameters) that correlated with clinical endpoints (6MWD, NT-proBNP, REVEAL Lite 2). Notable findings included statistically significant reductions in large arterial blood volume proportion (BV10A) and reductions in fibrosis-like parenchymal volume, and increases in total venous blood volume and venous branching.
Regulatory Progress: Type B Pre-NDA Meeting and NDA Timeline
FDA granted an in-person Type B pre-NDA meeting (briefing book submitted) scheduled for mid-June. Company is targeting an NDA submission in September 2026 and, if process proceeds as expected, a potential approval in Q3 2027.
Capital Structure Action: Convertible Note Exchange
Agreement terms would reduce outstanding convertible debt from $200 million to $72 million (a $128 million reduction, ~64% decrease) on a fully subscribed basis, extend maturity from 2027 to 2030, and issue new secured convertible notes bearing 7.5% cash interest (paid semiannually). Early tender incentives include equity consideration and warrants.
Cost Containment and Focus on NDA Execution
Company implemented rapid cost stewardship actions (including a targeted reduction in force and pausing non-essential development) to preserve runway and focus resources on NDA submission and potential commercialization.
GOSS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GOSS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 18, 2026 | $0.34 | $0.19 | -43.53% |
Mar 17, 2026 | $0.47 | $0.43 | -7.86% |
Nov 05, 2025 | $2.37 | $2.31 | -2.53% |
Aug 05, 2025 | $2.16 | $1.98 | -8.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Gossamer Bio (GOSS) report earnings?
Gossamer Bio (GOSS) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Gossamer Bio (GOSS) earnings time?
Gossamer Bio (GOSS) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GOSS EPS forecast?
GOSS EPS forecast for the fiscal quarter 2026 (Q2) is -0.12.